BEQOM
beqom, a cloud-based compensation software provider, has developed the first plug-and-play dynamic Total Rewards Statements . With this release, beqom will offer cost-effective, best-in-class reports that show employees their true value, boosting retention and engagement. Organizations upload data from their existing HRIT landscape, without burdening IT or disrupting current technology or processes, and receive individualized, dynamic statements in a matter of hours.
Turnover is often due to an employee’s perception of whether they are appreciated or paid fairly. Research shows that only two in five workers think their employer has a compelling value proposition, leading to retention issues of top performing talent. The quest for a great employee experience is centered around a business need for long-term engagement, retention, and productivity.
By providing dynamic employee self-service reward statements for all employees globally, HR leaders can see a direct boost in employee engagement, increase the company’s competitive position as an employer, and generate immediate ROI for their digital HR transformation.
“Showing your employees all the ways you reward them can defend against voluntary attrition, and, unlike enterprise-wide systems that take years to implement, the total rewards statements can boost employee satisfaction in days, with statements that start at $0.17 per employee per month,” says Tanya Jansen, beqom CMO.
This latest release builds on beqom’s decade of experience in compensation technology and asserts beqom as the leader in total rewards management. Total Rewards Statements will enable organizations to immediately supercharge HR teams’ efficiency through automation and to give employees the pay transparency they want in an on-demand, always-on experience.
The beqom Total Compensation Solution has helped Capgemini, BNP Paribas, McDonald's, Pepsico, and Yellow Pages provide their employees with a global vision of all elements related to compensation and sales performance management . The platform currently manages $300 billion in compensation for more than three million users in 160 countries.
About beqom:
Happiness is the best driver for success.
Our mission is to make
the workforce of our customers happy. beqom drives happiness by allowing
business managers to lead, align and motivate employees and partners.
beqom’s cloud-based total compensation platform is used globally across
all industry sectors by over 100 large companies such as Microsoft and
Vodafone. It addresses all performance and compensation aspects such as
salary review, bonus, long-term incentives, commissions, benefits,
non-cash rewards and all key drivers towards Employee Performance
Management and Sales Performance Management. HR, sales and finance
organizations leverage our platform to drive performance, retention,
cost optimization and…happiness among their people. beqom – to make your
people happy.
Learn more at www.beqom.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190307005290/en/
Contact:
Katherine McCabe, +1 408 899 0140 Katherine.mccabe@beqom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom